Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mavorixafor trihydrochloride is a selective and orally available CXCR4 antagonist (IC50: 13 nM against CXCR4 125I-SDF binding) and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs (IC50s: 1 and 9 nM).
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
2 mg | 約 5 days | ¥ 20,000 |
25 mg | 約6-8 週間 | ¥ 150,000 |
50 mg | 約6-8 週間 | ¥ 194,500 |
100 mg | 約6-8 週間 | ¥ 319,000 |
ターゲット&IC50 | HIV-1 (NL4.3 strain):9 nM (in PBMCs), HIV-1:26 nM (IC90, in PBMCs), HIV-1 (NL4.3 strain):1 nM (in MT-4 cells), HIV-1 (NL4.3 strain):3 nM (IC90, in MT-4 cells), [125I]-SDF-CXCR4:13 nM |
In vivo | Mavorixafor, at a dosage of 2 mg/kg administered orally, substantially decreases the count of metastatic lung nodules in mice while concurrently reducing the expression of human Alu DNA, all without causing loss in body weight [2]. |
別名 | AMD-070 trihydrochloride |
分子量 | 458.86 |
分子式 | C21H30Cl3N5 |
CAS No. | 2309699-17-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 6 mg/mL (13.08 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Mavorixafor trihydrochloride 2309699-17-8 Microbiology/Virology Proteases/Proteasome HIV Protease AMD-070 trihydrochloride AMD-070 AMD 070 Trihydrochloride AMD-070 Trihydrochloride AMD 070 Mavorixafor AMD070 Trihydrochloride Mavorixafor Trihydrochloride AMD070 Inhibitor inhibitor inhibit